Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research report released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Barclays cut their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th.

Cellectis Stock Performance

Cellectis stock opened at $1.87 on Wednesday. The company’s 50-day moving average price is $2.01 and its 200-day moving average price is $2.24. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. The company has a market cap of $103.93 million, a PE ratio of -1.44 and a beta of 3.10. Cellectis has a twelve month low of $1.70 and a twelve month high of $3.77.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The company had revenue of $18.05 million for the quarter, compared to the consensus estimate of $5.00 million. Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. During the same period in the previous year, the firm earned ($0.31) earnings per share. On average, equities research analysts forecast that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Trading of Cellectis

Several institutional investors and hedge funds have recently made changes to their positions in the business. XTX Topco Ltd bought a new position in shares of Cellectis in the second quarter worth about $29,000. First Affirmative Financial Network purchased a new stake in Cellectis in the 3rd quarter valued at about $45,000. Principal Financial Group Inc. boosted its position in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the period. Finally, Long Focus Capital Management LLC grew its stake in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after acquiring an additional 130,000 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.